In Part 2, we explore the current landscape of self-amplifying mRNA (sa-mRNA) "vaccines" by examining their underlying mechanisms and the implications of using RdRP backbones in their production.
These vaccines utilize a stripped-down viral sequence containing only the RdRP complex, aiming to reduce the required vaccine solution while facilitating long-term replication of the desired antigenic protein.
However, the potential for RdRP inhibition through protocols or drugs raises questions about the effectiveness of these vaccines and the implications for vaccine mandates.
There's a suggestion that those implementing early RdRP inhibiting treatments may achieve freedom from mandates and also acquire protection against wild RNA viruses, exposing potential flaws in the current vaccination strategies.
This poses challenges for Big Pharma, as continued demonization of early treatments could lead to global scandal and undermine trust in their products, ultimately risking their financial interests and public image.
Source: Self-Amplifying mRNA Part 2